{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:59:58Z","timestamp":1789757998154,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11936-020-00867-1","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T01:03:06Z","timestamp":1604365386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Cardiotoxicity of Contemporary Anticancer Immunotherapy"],"prefix":"10.1007","volume":"22","author":[{"given":"Natalie","family":"Dal\u2019bo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avirup","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourbha S.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0296-6864","authenticated-orcid":false,"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"issue":"8","key":"867_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"issue":"26","key":"867_CR2","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1104621.","journal-title":"N Engl J Med"},{"issue":"5","key":"867_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"issue":"26","key":"867_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"1","key":"867_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"4","key":"867_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccl.2019.07.008","volume":"37","author":"S Ganatra","year":"2019","unstructured":"Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of immune therapy. Cardiol Clin. 2019;37(4):385\u201397. https:\/\/doi.org\/10.1016\/j.ccl.2019.07.008.","journal-title":"Cardiol Clin"},{"key":"867_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018;23:879\u201386. https:\/\/doi.org\/10.1634\/theoncologist.2018-0130.","journal-title":"Oncologist."},{"issue":"25","key":"867_CR8","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","volume":"74","author":"S Ganatra","year":"2019","unstructured":"\u2022\u2022 Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC Council perspectives. J Am Coll Cardiol. 2019;74(25):3153\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.049 This is an American College of Cardiology (ACC) Cardio-Oncology council perspective on cardiovascular effects of CAR T-cell therapy with proposed pre-CAR T cell therapy workup and management strategies.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"867_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"issue":"16","key":"867_CR10","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"\u2022\u2022 Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037 This paper encompasses the data from international ICI-associated myocarditis registry and delineates risk factors, sensitivity, and specificity of various diagnostic tests and treatment strategies.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"867_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","volume":"18","author":"CR Maldini","year":"2018","unstructured":"Maldini CR, Ellis GI, Riley JL. CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol. 2018;18(10):605\u201316. https:\/\/doi.org\/10.1038\/s41577-018-0042-2.","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"867_CR12","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74(25):3099\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.038.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"867_CR13","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1609214.","journal-title":"N Engl J Med"},{"issue":"3","key":"867_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","volume":"101","author":"VA Love","year":"2007","unstructured":"Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res. 2007;101(3):248\u201357. https:\/\/doi.org\/10.1161\/CIRCRESAHA.106.147124.","journal-title":"Circ Res"},{"issue":"5502","key":"867_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319\u201322. https:\/\/doi.org\/10.1126\/science.291.5502.319.","journal-title":"Science."},{"issue":"12","key":"867_CR16","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9(12):1477\u201383. https:\/\/doi.org\/10.1038\/nm955.","journal-title":"Nat Med"},{"issue":"18","key":"867_CR17","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","volume":"116","author":"N Grabie","year":"2007","unstructured":"Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007;116(18):2062\u201371. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.709360.","journal-title":"Circulation."},{"issue":"21","key":"867_CR18","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030571.","journal-title":"Circulation."},{"issue":"8","key":"867_CR19","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1634\/theoncologist.2017-0452","volume":"23","author":"M Sarocchi","year":"2018","unstructured":"Sarocchi M, Grossi F, Arboscello E, Bellodi A, Genova C, Dal Bello MG, et al. Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist. 2018;23(8):936\u201342. https:\/\/doi.org\/10.1634\/theoncologist.2017-0452.","journal-title":"Oncologist."},{"issue":"1","key":"867_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-018-0353-7","volume":"6","author":"H L\u00e4ubli","year":"2018","unstructured":"L\u00e4ubli H, Balmelli C, Kaufmann L, Stanczak M, Syedbasha M, Vogt D, et al. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. J Immunother Cancer. 2018;6(1):40. https:\/\/doi.org\/10.1186\/s40425-018-0353-7.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"867_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-019-0535-y","volume":"7","author":"M Awadalla","year":"2019","unstructured":"Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, et al. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):53. https:\/\/doi.org\/10.1186\/s40425-019-0535-y.","journal-title":"J Immunother Cancer"},{"key":"867_CR22","unstructured":"Lee C, Zafar A, Drobni ZD, et al. Pre-existing cardiovascular risk factors are associated with the development of immune checkpoint inhibitor myocarditis. AHA Abstract. 2020;Submitted."},{"issue":"5","key":"867_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","volume":"75","author":"M Awadalla","year":"2020","unstructured":"Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. 2020;75(5):467\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.049.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"867_CR24","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.072.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"867_CR25","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733\u201343. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa051.","journal-title":"Eur Heart J"},{"issue":"10","key":"867_CR26","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/S0025-6196(12)61286-5","volume":"64","author":"AJ Hauck","year":"1989","unstructured":"Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc. 1989;64(10):1235\u201345.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"867_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s000590050007","volume":"25","author":"B Maisch","year":"2000","unstructured":"Maisch B, Portig I, Ristic A, Hufnagel G, Pankuweit S. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report. Herz. 2000;25(3):200\u20139.","journal-title":"Herz."},{"issue":"24","key":"867_CR28","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/circulationaha.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"\u2022\u2022 Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020;141(24):2031\u20134. https:\/\/doi.org\/10.1161\/circulationaha.119.044703 This manuscript demonstrates the importance of prompt initiation of high-dose corticosteroids for the treatment of ICI-associated myocarditis.","journal-title":"Circulation"},{"issue":"10","key":"867_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","volume":"138","author":"HJ Kwon","year":"2003","unstructured":"Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138(10):807\u201311.","journal-title":"Ann Intern Med"},{"issue":"24","key":"867_CR30","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377\u20139. https:\/\/doi.org\/10.1056\/NEJMc1901677.","journal-title":"N Engl J Med"},{"issue":"24","key":"867_CR31","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","volume":"380","author":"K Esfahani","year":"2019","unstructured":"Esfahani K, Buhlaiga N, Th\u00e9bault P, Lapointe R, Johnson NA, Miller WH. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med. 2019;380(24):2375\u20136. https:\/\/doi.org\/10.1056\/NEJMc1903064.","journal-title":"N Engl J Med"},{"issue":"10124","key":"867_CR32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6.","journal-title":"Lancet."},{"issue":"17","key":"867_CR33","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","journal-title":"J Clin Oncol"},{"issue":"1","key":"867_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29(1):250\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdx642.","journal-title":"Ann Oncol"},{"issue":"4","key":"867_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548.","journal-title":"Cancer Discov"},{"issue":"1","key":"867_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"issue":"18","key":"867_CR37","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1817226.","journal-title":"N Engl J Med"},{"issue":"8","key":"867_CR38","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","volume":"24","author":"DS Burstein","year":"2018","unstructured":"Burstein DS, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience. Biol Blood Marrow Transplant. 2018;24(8):1590\u20135. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.014.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9404","key":"867_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","volume":"363","author":"N Pathan","year":"2004","unstructured":"Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004;363(9404):203\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(03)15326-3.","journal-title":"Lancet."},{"issue":"197","key":"867_CR40","doi-asserted-by":"publisher","first-page":"197ra03","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra03. https:\/\/doi.org\/10.1126\/scitranslmed.3006034.","journal-title":"Sci Transl Med"},{"issue":"21","key":"867_CR41","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u2013306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141.","journal-title":"Blood."},{"key":"867_CR42","doi-asserted-by":"crossref","unstructured":"Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik G, et al. Chimeric antigen receptor T-cell therapy associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020;In Press.","DOI":"10.1161\/CIRCULATIONAHA.120.048100"},{"issue":"2","key":"867_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","volume":"2","author":"B Lefebvre","year":"2020","unstructured":"Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M. Cardiovascular effects of CAR T cell therapy. A retrospective study. JACC: CardioOncol. 2020;2(2):193\u2013203. https:\/\/doi.org\/10.1016\/j.jaccao.2020.04.012.","journal-title":"JACC: CardioOncol"},{"issue":"8","key":"867_CR44","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028.","journal-title":"Oncologist."},{"key":"867_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","volume":"15","author":"LL Riegler","year":"2019","unstructured":"Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;15:323\u201335. https:\/\/doi.org\/10.2147\/TCRM.S150524.","journal-title":"Ther Clin Risk Manag"},{"issue":"Suppl 1","key":"867_CR46","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","volume":"130","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory,aggressive non-Hodgkin lymphoma (NHL). Blood. 2017;130(Suppl 1):1547.","journal-title":"Blood"},{"key":"867_CR47","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jaccao.2020.03.001","volume":"80","author":"S Ganatra","year":"2020","unstructured":"Ganatra S, Hammond SP, Nohria A. The novel coronavirus disease (COVID-19) threat for patients with cardiovascular disease and cancer. JACC: CardioOncol. 2020;80:350\u20135. https:\/\/doi.org\/10.1016\/j.jaccao.2020.03.001.","journal-title":"JACC: CardioOncol"},{"key":"867_CR48","unstructured":"Ganatra S, Dani S, Redd R, Rieger-Christ K, Patel R, Parikh R, et al. Outcomes of the novel coronavirus disease 2019 in patients with a history of cancer and co-morbid cardiovascular disease. J Natl Compr Canc Netw. 2020;In Press."},{"key":"867_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.tcm.2020.05.004","volume":"30","author":"S Ganatra","year":"2020","unstructured":"Ganatra S, Dani SS, Shah S, Asnani A, Neilan TG, Lenihan D, et al. Management of cardiovascular disease during coronavirus disease (COVID-19) pandemic. Trends Cardiovasc Med. 2020;30:315\u201325. https:\/\/doi.org\/10.1016\/j.tcm.2020.05.004.","journal-title":"Trends Cardiovasc Med"},{"key":"867_CR50","doi-asserted-by":"crossref","unstructured":"Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P et al. Cardio-oncology care in the era of the coronavirus (COVID-19) pandemic: an International Cardio-Oncology Society (ICOS) statement on cardiac safety in a new treatment paradigm. CA Cancer J Clin. 2020;In Press.","DOI":"10.3322\/caac.21635"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-020-00867-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11936-020-00867-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-020-00867-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:18:18Z","timestamp":1744179498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11936-020-00867-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1007\/s11936-020-00867-1","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"5 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Natalie Dal\u2019bo, Rushin Patel, Rohan Parikh, Sachin P. Shah, Avirup Guha, Sourbha S. Dani, and Sarju Ganatra declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal rights and informed consent"}}],"article-number":"62"}}